BRPI0718322A2 - METHODS FOR DIAGNOSISING A SUSTAINABILITY FOR CANCER IN A HUMAN INDIVIDUAL, TO IDENTIFY A MARKER FOR USE IN THE ASSESSMENT OF CANCER SUSCETIBILITY, TO GENOTYPE A NUCLEIC ACID SAMPLE TO EVALUATE A UNAUTOUS WATERPROOFER IN A HUMAN RESIDENCE THE PROGNOSIS AND TO MONITOR THE PROGRESS OF A TREATMENT OF AN INDIVIDUAL, KIT TO EVALUATE THE SUSCETIBILITY FOR CANCER IN AN INDIVIDUAL, USE OF AN OLIGONUCLEOTIDE PROBE, MEDIA LEGIBLE BY COMPUTER, AND, DEVICE TO INDICATE A INDICATOR IN AN INDICATOR. . - Google Patents
METHODS FOR DIAGNOSISING A SUSTAINABILITY FOR CANCER IN A HUMAN INDIVIDUAL, TO IDENTIFY A MARKER FOR USE IN THE ASSESSMENT OF CANCER SUSCETIBILITY, TO GENOTYPE A NUCLEIC ACID SAMPLE TO EVALUATE A UNAUTOUS WATERPROOFER IN A HUMAN RESIDENCE THE PROGNOSIS AND TO MONITOR THE PROGRESS OF A TREATMENT OF AN INDIVIDUAL, KIT TO EVALUATE THE SUSCETIBILITY FOR CANCER IN AN INDIVIDUAL, USE OF AN OLIGONUCLEOTIDE PROBE, MEDIA LEGIBLE BY COMPUTER, AND, DEVICE TO INDICATE A INDICATOR IN AN INDICATOR. .Info
- Publication number
- BRPI0718322A2 BRPI0718322A2 BRPI0718322-4A2A BRPI0718322A BRPI0718322A2 BR PI0718322 A2 BRPI0718322 A2 BR PI0718322A2 BR PI0718322 A BRPI0718322 A BR PI0718322A BR PI0718322 A2 BRPI0718322 A2 BR PI0718322A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- individual
- suscetibility
- evaluate
- indicator
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 3
- 201000011510 cancer Diseases 0.000 title 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 title 1
- 239000003550 marker Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 239000002751 oligonucleotide probe Substances 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
- 239000000523 sample Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS8560 | 2006-10-27 | ||
| PCT/IS2007/000019 WO2008050356A1 (en) | 2006-10-27 | 2007-10-26 | Cancer susceptibility variants on chr8q24.21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0718322A2 true BRPI0718322A2 (en) | 2013-11-26 |
Family
ID=39060300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0718322-4A2A BRPI0718322A2 (en) | 2006-10-27 | 2007-10-26 | METHODS FOR DIAGNOSISING A SUSTAINABILITY FOR CANCER IN A HUMAN INDIVIDUAL, TO IDENTIFY A MARKER FOR USE IN THE ASSESSMENT OF CANCER SUSCETIBILITY, TO GENOTYPE A NUCLEIC ACID SAMPLE TO EVALUATE A UNAUTOUS WATERPROOFER IN A HUMAN RESIDENCE THE PROGNOSIS AND TO MONITOR THE PROGRESS OF A TREATMENT OF AN INDIVIDUAL, KIT TO EVALUATE THE SUSCETIBILITY FOR CANCER IN AN INDIVIDUAL, USE OF AN OLIGONUCLEOTIDE PROBE, MEDIA LEGIBLE BY COMPUTER, AND, DEVICE TO INDICATE A INDICATOR IN AN INDICATOR. . |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100129799A1 (en) |
| EP (1) | EP2089548A1 (en) |
| JP (1) | JP5631000B2 (en) |
| CN (1) | CN101641451A (en) |
| AU (1) | AU2007310412B2 (en) |
| BR (1) | BRPI0718322A2 (en) |
| CA (1) | CA2667737A1 (en) |
| IL (1) | IL198305A0 (en) |
| MX (1) | MX2009004522A (en) |
| NZ (1) | NZ576591A (en) |
| SG (1) | SG175680A1 (en) |
| WO (1) | WO2008050356A1 (en) |
| ZA (1) | ZA200903173B (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8865400B2 (en) * | 2007-02-07 | 2014-10-21 | Decode Genetics Ehf. | Genetic variants contributing to risk of prostate cancer |
| US8431345B2 (en) | 2007-04-17 | 2013-04-30 | Shigeru Kinoshita | Method for determination of progression risk of glaucoma |
| US8697360B2 (en) | 2007-11-30 | 2014-04-15 | Decode Genetics Ehf. | Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition |
| US20090226912A1 (en) * | 2007-12-21 | 2009-09-10 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| EP2313525A2 (en) * | 2008-07-07 | 2011-04-27 | Decode Genetics EHF | Genetic variants for breast cancer risk assessment |
| EP2318552B1 (en) | 2008-09-05 | 2016-11-23 | TOMA Biosciences, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| EP2347009A4 (en) * | 2008-10-14 | 2012-05-30 | Caris Mpi Inc | GENETIC AND PROTEIN TARGETS EXPRESSED BY GENES REPRESENTING BIOMARKER PROFILES AND SIGNATURE SETS BY TYPE OF TUMORS |
| WO2010128530A1 (en) * | 2009-05-08 | 2010-11-11 | Decode Genetics Ehf | Genetic variants contributing to risk of prostate cancer |
| WO2011004404A1 (en) * | 2009-07-10 | 2011-01-13 | Decode Genetics Ehf | Genetic variants for predicting risk of glaucoma |
| US20120316218A1 (en) * | 2009-07-17 | 2012-12-13 | Glinsky Gennadi V | SMALL NON-CODING REGULARTORY RNA's and METHODS FOR THEIR USE |
| WO2011009089A1 (en) * | 2009-07-17 | 2011-01-20 | Ordway Research Institute, Inc. | SMALL NON-CODING REGULATORY RNAs AND METHODS FOR THEIR USE |
| CA2777169C (en) * | 2009-10-26 | 2018-11-20 | Abbott Laboratories | Diagnostic methods for determining prognosis of non-small cell lung cancer |
| MX2012004907A (en) | 2009-10-26 | 2012-06-14 | Abbott Lab | Diagnostic methods for determining prognosis of non-small cell lung cancer. |
| WO2012029080A1 (en) * | 2010-08-30 | 2012-03-08 | Decode Genetics Ehf | Sequence variants associated with prostate specific antigen levels |
| US9732389B2 (en) | 2010-09-03 | 2017-08-15 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| CA2810931C (en) | 2010-09-24 | 2018-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target dna using immobilized primers |
| US9534256B2 (en) | 2011-01-06 | 2017-01-03 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer |
| CA2826748C (en) * | 2011-02-09 | 2020-08-04 | Bio-Rad Laboratories, Inc. | Method of detecting variations in copy number of a target nucleic acid |
| CN102304567B (en) * | 2011-04-29 | 2013-03-27 | 广州益善生物技术有限公司 | Polymorphic detection specific primers and liquid phase chip in 8 q 24 section of chromosome |
| WO2012178058A1 (en) * | 2011-06-22 | 2012-12-27 | Indiana University Research And Technology Corporation | Compositions for and methods of detecting, diagnosing and prognosing thymic cancer |
| WO2013065072A1 (en) * | 2011-10-30 | 2013-05-10 | Decode Genetics Ehf | Risk variants of prostate cancer |
| CN105555972B (en) | 2013-07-25 | 2020-07-31 | 伯乐生命医学产品有限公司 | Genetic assay |
| JP6883584B2 (en) * | 2015-08-27 | 2021-06-09 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | Integrated methods and systems for identifying functional patient-specific somatic abnormalities using multiomic cancer profiles |
| WO2017164699A1 (en) * | 2016-03-24 | 2017-09-28 | 서울대학교병원 (분사무소) | Prostate cancer-related single nucleotide polymorphism and development of genetic risk score by using same |
| KR101944927B1 (en) | 2016-03-24 | 2019-02-07 | 서울대학교산학협력단 | Single Nucleotide Polymorphisms Associated With Korean Prostate Cancer And Development Of Genetic Risk Score Using Thereof |
| CN106480211A (en) * | 2016-11-24 | 2017-03-08 | 深圳市核子基因科技有限公司 | A kind of kit and its SNP mark for detection of testis cancer neurological susceptibility |
| JP7138112B2 (en) * | 2017-02-01 | 2022-09-15 | ファディア・アクチボラゲット | Methods for indicating the presence or absence of prostate cancer in individuals with certain characteristics |
| WO2020111169A1 (en) * | 2018-11-28 | 2020-06-04 | 国立大学法人千葉大学 | Genetic testing method for multifactorial genetic disease and testing kit |
| EP3963092A1 (en) * | 2019-05-02 | 2022-03-09 | Predictive Technology Group, Inc. | Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk |
| US20230119558A1 (en) * | 2020-03-06 | 2023-04-20 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Dna damage repair genes in cancer |
| KR102177222B1 (en) * | 2020-04-24 | 2020-11-10 | 유니젠바이오 주식회사 | System for predicting cancer diagnosis based on machine learning |
| KR102177218B1 (en) * | 2020-04-24 | 2020-11-10 | 유니젠바이오 주식회사 | Apparatus for predicting cancer diagnosis based on machine learning |
| KR20250074712A (en) | 2023-11-15 | 2025-05-28 | 주식회사 바스젠바이오 | Composition for predicting a risk of developing prostate cancer and method using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5384261A (en) * | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| AU785425B2 (en) * | 2001-03-30 | 2007-05-17 | Genetic Technologies Limited | Methods of genomic analysis |
| CA2460215A1 (en) * | 2001-08-04 | 2003-02-20 | Whitehead Institute For Biomedical Research | Haplotype map of the human genome and uses therefor |
| US20040023237A1 (en) * | 2001-11-26 | 2004-02-05 | Perelegen Sciences Inc. | Methods for genomic analysis |
| US20040146870A1 (en) * | 2003-01-27 | 2004-07-29 | Guochun Liao | Systems and methods for predicting specific genetic loci that affect phenotypic traits |
-
2007
- 2007-10-26 CA CA002667737A patent/CA2667737A1/en not_active Abandoned
- 2007-10-26 BR BRPI0718322-4A2A patent/BRPI0718322A2/en not_active IP Right Cessation
- 2007-10-26 EP EP20070827611 patent/EP2089548A1/en not_active Withdrawn
- 2007-10-26 JP JP2009534057A patent/JP5631000B2/en not_active Expired - Fee Related
- 2007-10-26 AU AU2007310412A patent/AU2007310412B2/en not_active Ceased
- 2007-10-26 CN CN200780046943A patent/CN101641451A/en active Pending
- 2007-10-26 WO PCT/IS2007/000019 patent/WO2008050356A1/en active Application Filing
- 2007-10-26 NZ NZ576591A patent/NZ576591A/en not_active IP Right Cessation
- 2007-10-26 SG SG2011078417A patent/SG175680A1/en unknown
- 2007-10-26 US US12/442,254 patent/US20100129799A1/en not_active Abandoned
- 2007-10-26 MX MX2009004522A patent/MX2009004522A/en active IP Right Grant
-
2009
- 2009-04-22 IL IL198305A patent/IL198305A0/en unknown
- 2009-05-07 ZA ZA2009/03173A patent/ZA200903173B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2667737A1 (en) | 2008-05-02 |
| AU2007310412A1 (en) | 2008-05-02 |
| US20100129799A1 (en) | 2010-05-27 |
| IL198305A0 (en) | 2010-02-17 |
| AU2007310412B2 (en) | 2013-02-14 |
| SG175680A1 (en) | 2011-11-28 |
| JP2010507388A (en) | 2010-03-11 |
| NZ576591A (en) | 2012-04-27 |
| JP5631000B2 (en) | 2014-11-26 |
| CN101641451A (en) | 2010-02-03 |
| EP2089548A1 (en) | 2009-08-19 |
| MX2009004522A (en) | 2009-07-02 |
| WO2008050356A1 (en) | 2008-05-02 |
| ZA200903173B (en) | 2010-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0718322A2 (en) | METHODS FOR DIAGNOSISING A SUSTAINABILITY FOR CANCER IN A HUMAN INDIVIDUAL, TO IDENTIFY A MARKER FOR USE IN THE ASSESSMENT OF CANCER SUSCETIBILITY, TO GENOTYPE A NUCLEIC ACID SAMPLE TO EVALUATE A UNAUTOUS WATERPROOFER IN A HUMAN RESIDENCE THE PROGNOSIS AND TO MONITOR THE PROGRESS OF A TREATMENT OF AN INDIVIDUAL, KIT TO EVALUATE THE SUSCETIBILITY FOR CANCER IN AN INDIVIDUAL, USE OF AN OLIGONUCLEOTIDE PROBE, MEDIA LEGIBLE BY COMPUTER, AND, DEVICE TO INDICATE A INDICATOR IN AN INDICATOR. . | |
| BRPI0807927A2 (en) | METHODS FOR DETERMINING CARDIOVASCULAR DISEASE SUSTAINABILITY IN A HUMAN INDIVIDUAL, IDENTIFICATION OF A BOOKMARK FOR USE TO ASSESS CARDIOVASCULAR DISEASE, FOR GENOTIPAYING A SAMPLE OF A PREPARATILE FOR NUCLEAR PROBABLE ACTIVITY PROGNOSIS OF A DIAGNOSTIC INDIVIDUAL WITH CARDIOVASCULAR DISEASE, AND TO MONITOR PROGRESS OF TREATMENT OF AN INDIVIDUAL GOING TO TREATMENT FOR CARDIOVASCULAR DISEASE, A HUMAN DEVELOPMENT, CARDIOVASCULAR DISEASE , DEVICE FOR DETERMINING A GENETIC INDICATOR FOR CARDIOVASCULAR DISEASE IN A HUMAN GUY | |
| BRPI0807236A2 (en) | methods for determining prostate cancer susceptibility in a human individual, identifying a marker for use in prostate cancer susceptibility assessment, and for genotyping a nucleic acid sample obtained from a human individual at risk of, or diagnosed with, cancer to assess a human individual for likelihood of response to a therapeutic agent to prevent and / or ameliorate symptoms associated with prostate cancer, to predict prognosis of an individual diagnosed with cancer, and to monitor progress in treatment of an individual undergoing treatment. for prostate cancer, kit for assessing susceptibility to prostate cancer in a human individual, use of a computer readable oligonucleotide probe, and apparatus for determining a genetic indicator for prostate cancer in a human individual. | |
| Daughton | Using biomarkers in sewage to monitor community-wide human health: Isoprostanes as conceptual prototype | |
| BRPI0720116B8 (en) | method for determining a susceptibility to cardiac arrhythmia or stroke in a human subject, use of an oligonucleotide probe, and apparatus for determining a genetic indicator for cardiac arrhythmia and/or stroke in a human subject | |
| IN2014CN03228A (en) | ||
| PH12018550037A1 (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
| EP2319941A3 (en) | Method and apparatus for correlating levels of biomarker products with disease | |
| BR112014007214A2 (en) | prediction of cardiovascular risk event and its use | |
| PL3178559T3 (en) | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples | |
| BR112013003391A2 (en) | pancreatic cancer biomarkers and their uses | |
| BR112013014527A2 (en) | isolated antibody, isolated nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation, use of immunoconjugate, method for treating an individual who has mesothelin positive cancer, for inhibiting proliferation of a mesothelin positive cell, for detecting human mesothelin in a biological sample and for detecting mesothelin positive cancer | |
| BR112012009879A2 (en) | "diagnostic methods to determine prognosis of non-small cell lung cancer" | |
| BRPI0907637A8 (en) | p53 biomarkers | |
| EP1906135A4 (en) | PROBE FOR SHAPE MEASURING APPARATUS, AND FORM MEASURING APPARATUS | |
| BRPI1007321A2 (en) | methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody. | |
| ES2686300T3 (en) | Association of recurrent rare genetic variations with attention deficit hyperactivity disorder (ADHD) and procedures for their use for diagnosis and treatment. | |
| BRPI0915619A2 (en) | methods for determining a probability that a subject has contributed genetic material to the genetic material test sample, to characterize genetic material test sample, and to determine whether a person of interest has contributed genetic material to a genetic material test sample , genetic material test sample analysis kit, and system to determine if a subject has contributed genetic material to a sample | |
| BRPI0817008A2 (en) | oligonucleotide, primer or probe, primer pair, kit, methods for detecting the presence and / or amount of the unmethylated and methylated mage-a3 gene in a DNA-containing sample to diagnose cancer or cancer predisposition or cancer predisposition, to identify and / or select a suitable patient for treatment with a mage-a3 immunotherapeutic, to predict the likelihood of successful cancer treatment, to select an appropriate cancer treatment regimen, to treat cancer in a patient, to treat a patient susceptible to recurrence of a tumor expressing mage-a3, and use of a composition | |
| CL2008001517A1 (en) | Device for determining the risk of melanoma progression comprising oligonucleotides of one or more melanoma prognostic markers (mpms) chosen from a selection group; procedure for determining the prognosis of melanoma in a patient; Procedure for determining the suitability of a melanoma patient for a drug trial. | |
| BRPI0608429A2 (en) | method and kit for predicting or evaluating the effectiveness of treating a solid tumor in a patient of interest; and method for identifying markers that are prognostic for a solid tumor | |
| DE112007000683A5 (en) | Device for carrying out and testing biological samples with temperature-controlled biological reactions | |
| WO2009149026A3 (en) | Genomic approaches to fetal treatment and diagnosis | |
| BRPI0811930B8 (en) | methods and diagnostic or prognostic kit for lupus in an individual | |
| BR112014010463A2 (en) | method for detecting one or more dengue virus serotypes in a sample, dengue virus infection detection kit, isolated oligonucleotide, plurality of isolated oligonucleotides, process for diagnosing or confirming the diagnosis of the presence or absence of dengue virus in a individual, process for detecting the presence or absence of dengue virus in a sample and using a nucleic acid primer or probe to prepare a composition for diagnosing or confirming the presence or absence of dengue virus in an individual |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |